VENUSREM

Venus Remedies share price & financials

Price
₹1,739.1
Market cap
₹2.2k Cr
Sector
Healthcare

What Venus Remedies Limited does

Venus Remedies is a research-led pharmaceutical manufacturer headquartered in Panchkula, India, producing generic and speciality injectable and oral formulations across antimicrobial resistance (AMR), oncology, skin and wound care, neurology, pain management, anticoagulants, herbal therapeutics and disinfectants. It runs its own manufacturing units in India, plus Venus Pharma GmbH in Germany, and an in-house DSIR-accredited R&D centre, the Venus Medicine Research Centre (VMRC), which develops proprietary platforms such as Renal Guard Technology for anti-infectives. It earns through direct sales, government/institutional tenders (e.g., UNICEF, PAHO) and regulatory-approval-driven exports across 90+ countries, alongside a domestic trade-generics network of stockists and retailers. A plant-based wellness brand, RESET, sits alongside its core prescription and critical-care portfolio.

Segments

  • Domestic formulations (Trade Generics)
  • International business
  • Consumer wellness (RESET)
Global presence
90+ countries
Manufacturing facilities
3 (India, plus Venus Pharma GmbH, Germany)
Installed injectable manufacturing capacity
100 mn units per annum
Marketing authorisations held
1,050+
Product basket
180+ formulations
Hospital reach
12,000+ hospitals
Founded 1989Headquarters Panchkula, India Company website

Quarterly results

Q1 FY27: revenue up 30.7%, net profit up 130.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue170 177 195 137 193 +14%180 +2%259 +33%179 +31%
EBITDA8 18 29 15 31 +288%38 +111%63 +117%34 +127%
Net profit4 20 21 10 20 +400%26 +30%48 +129%23 +130%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +256.1% 1Y

₹0.5k₹1.0k₹1.5k₹2.0kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹453.95 on 10 Sept 2025 → ₹1,616.3. High ₹1,947 (25 Jun 2026), low ₹431.3 (19 Sept 2025).

Financials, as filed

Revenue grew 11.4% a year over 3 years, FY23 to FY26. Operating margin widened to 19.1%.

Year endingFY23FY24FY25FY26
Revenue₹556 Cr₹601 Cr₹651 Cr₹769 Cr
Operating profit₹61 Cr₹59 Cr₹66 Cr₹147 Cr
Operating margin10.9%9.8%10.1%19.1%
Interest₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Depreciation₹32 Cr₹27 Cr₹22 Cr₹26 Cr
Net profit₹26 Cr₹29 Cr₹46 Cr₹104 Cr
Net margin4.7%4.8%7.1%13.5%
Cash from operations₹37 Cr₹37 Cr₹86 Cr₹156 Cr
Free cash flow₹29 Cr₹24 Cr₹69 Cr₹118 Cr
ROCE8.0%9.0%11.0%22.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹12 Cr₹13 Cr₹13 Cr₹13 Cr₹13 Cr₹13 Cr
Reserves₹388 Cr₹427 Cr₹447 Cr₹474 Cr₹581 Cr₹650 Cr
Borrowings₹51 Cr₹43 Cr₹42 Cr₹41 Cr₹14 Cr₹12 Cr
Other liabilities₹104 Cr₹97 Cr₹98 Cr₹98 Cr₹159 Cr₹178 Cr
Total liabilities₹556 Cr₹580 Cr₹601 Cr₹627 Cr₹768 Cr₹854 Cr
Fixed assets₹262 Cr₹241 Cr₹216 Cr₹219 Cr₹237 Cr₹232 Cr
Capital work in progress₹25 Cr₹25 Cr₹26 Cr₹21 Cr₹34 Cr₹51 Cr
Investments₹0 Cr₹0 Cr₹20 Cr₹19 Cr₹193 Cr₹238 Cr
Other assets₹269 Cr₹314 Cr₹339 Cr₹368 Cr₹303 Cr₹333 Cr
Total assets₹556 Cr₹580 Cr₹601 Cr₹627 Cr₹768 Cr₹854 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public trimmed −1.45 pp while DIIs added +0.78 pp. The shareholder count grew 13% to 21,905.

Promoters
41.8%
FIIs
2.9%
DIIs
0.9%
Public
54.4%

Since Jun 2025

  • Public −1.45 pp
  • DIIs +0.78 pp
  • FIIs +0.67 pp

How it drifted, 12 quarters

Over this window the public fell from 57.2% to 54.4% — −2.8 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 41.8%, FIIs 1.0%, Public 57.2%.Dec '23: Promoters 41.8%, FIIs 1.6%, Public 56.6%.Mar '24: Promoters 41.8%, FIIs 1.5%, Public 56.8%.Jun '24: Promoters 41.8%, FIIs 1.1%, Public 57.2%.Sep '24: Promoters 41.8%, FIIs 1.2%, Public 57.1%.Dec '24: Promoters 41.8%, FIIs 1.1%, Public 57.1%.Mar '25: Promoters 41.8%, FIIs 1.3%, Public 56.9%.Jun '25: Promoters 41.8%, FIIs 2.3%, DIIs 0.1%, Public 55.9%.Sep '25: Promoters 41.8%, FIIs 1.9%, DIIs 0.8%, Public 55.6%.Dec '25: Promoters 41.8%, FIIs 2.3%, DIIs 1.0%, Public 55.0%.Mar '26: Promoters 41.8%, FIIs 2.8%, DIIs 1.2%, Public 54.2%.Jun '26: Promoters 41.8%, FIIs 2.9%, DIIs 0.9%, Public 54.4%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 2 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Venus Remedies Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Sunev Pharma Solutions Pvt Ltd 17.21%unchanged
Pawan Chaudhary 12.82%unchanged
Manu Chaudhary 11.73%unchanged
Tikri Partners Llp 1.97%unchanged
Rajni Tarun Jain 1.42%unchanged
Acadian Emerging Markets Micro-Cap Equity Master Fund Global fund house1.10%unchanged
Nisarg Ajaykumar Vakharia 1.05%unchanged
Investor Education and Protection Fund (IEPF) 1.00%newly disclosed
Ekta Thakur 0.00%newly disclosed
Aditi K Chaudhary 0.00%newly disclosed
Saransh Chaudhary 0.00%newly disclosed
Venus Foundation Trust 0.00%newly disclosed

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Venus Remedies Limited

Guides on how to read this kind of business and the numbers that matter.